Navigation Links
Vion Pharmaceuticals Holds Special Meeting of Stockholders
Date:2/13/2008

ith temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of sub
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... 2014 Reportlinker.com announces that a new ... Global Chelating Agents Market 2014-2018 ... Chelating Agent A chelating agent is a chemical ... ions, thereby forming a metal-ion complex. It reduces ... chemical processes, formulations, and the environment by chelating ...
(Date:8/27/2014)... Aug. 27, 2014 Guggenheim Securities, the investment ... announced the hiring of veteran equity analyst Charles "Tony" ... Mr. Butler will focus on the biotech/biopharma sector. ... wealth of experience and a broad network of relationships ... Managing Director and Head of Equities at Guggenheim Securities. ...
(Date:8/27/2014)... 2014  ARCH Venture Partners, one of the ... development of seed and early-stage advanced technology companies, ... with more than $400 million in subscriptions. ARCH ... target by more than $150 million. ... and potential of our approach to finding and ...
(Date:8/27/2014)... August 27, 2014 According to the ... to reshape the look and feel of markets for ... for higher-quality ingredients will push for more branded, science-backed ... have experienced strong market growth in the last decade ... their food and cosmetics to fit a more ‘wellness’ ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 2Daring to be Different Raw Materials & Ingredient Supply Shortage Fuels Vital Force™ Technology New Ingredient Enhancements 3
... Whitewater, Wis. - The University of Wisconsin-Whitewater has ... what is now known as the Information Technology Infrastructure ... Computer End-User Technologies program, is a product of joint ... will begin this fall semester. It places a far ...
... Metavante Corp., the financial technology subsidiary of Marshall ... June, of Wayne, Pa.-based GHR Systems, Inc. , ... mortgage and consumer finance industries that offers point-of-sale products ... Systems will become a Metavante subsidiary. , ,GHR's client ...
... - Southern Wisconsin's biotech infrastructure has prompted a ... an operating facility that could employ approximately 200 people. ... the southern tier of Wisconsin to manufacture systems used ... CEO Dan Miller. It's a product that company representatives ...
Cached Biology Technology:Whitewater upgrades tech degree program 2Whitewater upgrades tech degree program 3Minneapolis company sets sights on southern Wisconsin 2Minneapolis company sets sights on southern Wisconsin 3
(Date:8/27/2014)... a dreaded bacterium that can be found in both ... 28 persons in Denmark have been infected with ... have died. , The bacterium is notoriously difficult to ... adapt to changes in its surroundings, says Associate Professor ... from the Department of Biochemistry and Molecular Biology, she ...
(Date:8/26/2014)... Researchers at Washington University in St. Louis have developed ... bones prone to tearing or breaking. The technology, which ... patients, one day may help pinpoint minor strains and ... problems occur. , The research is available online Aug. ... Interface , which publishes research at the nexus of ...
(Date:8/26/2014)... obtaining an unprecedented view of a type of ... of neurological illnesses, including Alzheimer,s disease, Parkinson,s disease, ... stroke. , The team of biologists at Cold ... Energy,s Advanced Photon Source at Argonne National Laboratory ... NMDA (N-methyl, D-aspartate) receptor should serve as template ...
Breaking Biology News(10 mins):Researchers discover why Listeria bacterium is so hard to fight 2Researchers discover why Listeria bacterium is so hard to fight 3New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 2Unprecedented detail of intact neuronal receptor offers blueprint for drug developers 3
... from McGill/MUHC and the CHUM have been awarded ... Institutes of Health Research (CIHR) to continue their ... during sexual intercourse. The new funding will allow ... and statistician/epidemiologists, to root-out the cause of a ...
... at Case Western Reserve University School of Medicine and University ... (FDA) has approved plans to begin a study to evaluate ... to treat chronic ischemia, a serious form of heart disease. ... to test the safety of the procedure. It will ...
... leading neuroscientist at MIT and one from the University ... Nov. 4 special issue of Science dedicated to the ... "protocortex" theories of brain development are dead. , The ... neurons divided into distinctly separate areas that process particular ...
Cached Biology News:MUHC investigators search for the root of sexual pain in women 2Feds give researchers ok for safety test of adult stem cells in patients with heart disease 2MIT researcher presents new view of how the cortex forms 2
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... LC Sciences provides a genome-wide microRNA ... and proprietary probe design, which enable highly ... (1-3). We have standard arrays for mature ... latest version of the Sanger miRBase database ...
... synthetic peptide whose sequences are derived from mouse resistin protein. ... - S - M - P - L - C - ... - D - K - K - I - K - ... used for neutralization and control experiments with the polyclonal antibody that ...
... Imaging System, Basic Package Superior Protein ... Range: The ProXPRESS 2D Proteomic Imaging System ... for both proteomic and general life science ... enabling the use of all dyes in ...
Biology Products: